Zura Bio stock analysis
Zura Bio (94E) Stock Price & Analysis
94E Stock Chart & Stats
- Day’s Range
- EUR 1.12 - EUR 1.12
- 52-Week Range
- EUR 1.06 - EUR 6.00
- Previous Close
- EUR 1.26
- Volume
- N/A
- Average Volume (3M)
- 93
- Market Cap
- EUR 108.37M
- Enterprise Value
- EUR 343.63M
- Total Cash (Recent Filing)
- EUR 187.65M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.91
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- -0.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
A zero-debt capital structure reduces near-term solvency and refinancing pressure while preserving flexibility to fund clinical development. Positive equity provides an additional financial buffer, although continued losses could gradually erode this strength if operating performance does not improve.
Clinical Funding Visibility
Cash runway through at least 2028 gives Zura the ability to advance multiple clinical programs toward important readouts without an immediately stated funding deadline. This supports continuity of execution and improves visibility across the next several development milestones.
Pipeline Progress
Progress in systemic sclerosis and preparation for the polymyalgia rheumatica study preserve multiple potential development paths despite the hidradenitis setback. Advancing programs across indications can diversify clinical outcomes and maintain strategic options over the medium term.
Bears Say
No Commercial Revenue
Zura has not yet demonstrated commercial revenue to offset research and corporate spending, while its TTM loss widened materially from 2025. This pre-revenue model leaves near-term financial performance dependent on clinical progress rather than an established earnings base.
Heavy Cash Burn
Deeply negative operating and free cash flow indicate that losses are translating directly into substantial funding needs. Even with a strong current cash position, sustained burn can reduce financial flexibility over time and increase reliance on future capital or successful clinical advancement.
Phase 2 Program Failure
The Phase 2 miss removes one development path and reduces the value of tibulizumab in hidradenitis suppurativa, while also exposing clinical execution and efficacy risk. Discontinuation narrows the pipeline and increases dependence on systemic sclerosis and polymyalgia rheumatica outcomes.
94E FAQ
What was Zura Bio’s price range in the past 12 months?
What is Zura Bio’s market cap?
When is Zura Bio’s upcoming earnings report date?
How were Zura Bio’s earnings last quarter?
Is Zura Bio overvalued?
Does Zura Bio pay dividends?
What is Zura Bio’s EPS estimate?
How many shares outstanding does Zura Bio have?
What happened to Zura Bio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zura Bio?
What is the TipRanks Smart Score and how is it calculated?
Zura Bio Stock Smart Score
Company Description
Zura Bio
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sandeep C. Kulkarni
- Employees
- 40
- Website
- zurabio.com
- Address
- 1489 W. Warm Springs Road, Henderson, NV, 89014, US
Zura Bio (94E) Earnings & Revenues
94E Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |










